Delisting riskPopularity #4,171
TScan Therapeutics (TCRX)
Develops TCR-engineered T-cell therapies for cancer through a T-cell receptor discovery platform.
$0.3535
vs last close−0.00 (−0.37%)
Something off on this page? Send us feedback.
Next report
Nov 11, 26
estimated · in 49 days
EPS estimate
−$0.26
Revenue estimate
$459.0K
Fiscal quarter
Q3 FY26
EPSReportedEstimate
Mar '25May '25Aug '25Nov '25Mar '26May '26Aug '26Nov '26
Reported−$0.29−$0.26−$0.28−$0.28−$0.18−$0.22−$0.23Pending
Estimate−$0.27−$0.28−$0.28−$0.35−$0.27−$0.22−$0.25−$0.26
Surprise−7.4%+7.1%0.0%+20.0%+33.3%0.0%+9.2%—
RevenueReportedEstimate
Mar '25May '25Aug '25Nov '25Mar '26May '26Aug '26Nov '26
Reported$665.0K$2.2M$3.1M$2.5M$2.6M$982.0K$1.1MPending
Estimate$1.5M$1.1M$1.9M$1.9M$2.4M$2.5M$1.9M$459.0K
Surprise−56.2%+100.1%+65.4%+29.4%+5.4%−60.7%−43.9%—
HistoryUpcoming
| Date / Period | Estimate | Reported | Surprise |
|---|---|---|---|
| Dec 2027 | −$0.17 | — | — |
| Sep 2027 | −$0.16 | — | — |
| Jun 2027 | −$0.16 | — | — |
| Mar 2027 | −$0.18 | — | — |
| Dec 2026 | −$0.21 | — | — |
| Nov 2026 | −$0.26 | — | — |
| Aug 2026 | −$0.25 | −$0.23 | +9.2% |
| May 2026 | −$0.22 | −$0.22 | 0.0% |
| Mar 2026 | −$0.27 | −$0.18 | +33.3% |
| Nov 2025 | −$0.35 | −$0.28 | +20.0% |
| Aug 2025 | |||
| May 2025 | |||
| Mar 2025 | |||
| Nov 2024 | |||
| Aug 2024 | |||
| May 2024 | |||
| Mar 2024 | |||
| Nov 2023 | |||
| Aug 2023 | |||
| May 2023 | |||
| Mar 2023 | |||
| Nov 2022 | |||
| Aug 2022 | |||
| May 2022 | |||
| Mar 2022 | |||
| Nov 2021 | |||
| Aug 2021 | |||
| Jul 2021 | |||
| Dec 2020 | |||
| Sep 2020 | |||
| Jun 2020 | |||
| Mar 2020 |
| Date / Period | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Reaction |
|---|---|---|---|---|---|---|---|
| Dec 2027 | −$0.17 | — | — | $812.5K | — | — | — |
| Sep 2027 | −$0.16 | — | — | $812.5K | — | — | — |
| Jun 2027 | −$0.16 | — | — | $937.5K | — | — | — |
| Mar 2027 | −$0.18 | — | — | $937.5K | — | — | — |
| Dec 2026 | −$0.21 | — | — | $929.3K | — | — | — |
| Nov 11, 2026 | −$0.26 | — | — | $459.0K | — | — | — |
| Aug 12, 2026 | −$0.25 | −$0.23 | +9.2% | $1.9M | $1.1M | −43.9% | −0.5% |
| May 6, 2026 | −$0.22 | −$0.22 | 0.0% | $2.5M | $982.0K | −60.7% | +3.3% |
| Mar 4, 2026 | −$0.27 | −$0.18 | +33.3% | $2.4M | $2.6M | +5.4% | +4.9% |
| Nov 12, 2025 | −$0.35 | −$0.28 | +20.0% | $1.9M | $2.5M | +29.4% | −2.5% |
| Aug 12, 2025 | |||||||
| May 6, 2025 | |||||||
| Mar 5, 2025 | |||||||
| Nov 12, 2024 | |||||||
| Aug 12, 2024 | |||||||
| May 13, 2024 | |||||||
| Mar 6, 2024 | |||||||
| Nov 9, 2023 | |||||||
| Aug 10, 2023 | |||||||
| May 10, 2023 | |||||||
| Mar 8, 2023 | |||||||
| Nov 9, 2022 | |||||||
| Aug 10, 2022 | |||||||
| May 9, 2022 | |||||||
| Mar 9, 2022 | |||||||
| Nov 10, 2021 | |||||||
| Aug 19, 2021 | |||||||
| Jul 15, 2021 | |||||||
| Dec 31, 2020 | |||||||
| Sep 30, 2020 | |||||||
| Jun 30, 2020 | |||||||
| Mar 31, 2020 |